📣 VC round data is live. Check it out!

Precision BioSciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Precision BioSciences and similar public comparables like Pyridam Farma, PhotoCure, Atrium Therapeutics, Camp4 Therapeutics and more.

Precision BioSciences Overview

About Precision BioSciences

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.


Founded

2006

HQ

United States

Employees

108

Financials (LTM)

Revenue: $27M
EBITDA: ($54M)

EV

$110M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Precision BioSciences Financials

Precision BioSciences reported last 12-month revenue of $27M and negative EBITDA of ($54M).

In the same LTM period, Precision BioSciences generated $27M in gross profit, ($54M) in EBITDA losses, and had net loss of ($54M).

Revenue (LTM)


Precision BioSciences P&L

In the most recent fiscal year, Precision BioSciences reported revenue of $34M and EBITDA of ($42M).

Precision BioSciences is unprofitable as of last fiscal year, with EBITDA margin of (124%) and net margin of (133%).

See analyst estimates for Precision BioSciences
LTMLast FY202320242025202620272028
Revenue$27M$34M$49M$69M$34M
Gross Profit$27M————
Gross Margin100%————
EBITDA($54M)($42M)($32M)$14M($42M)
EBITDA Margin(199%)(124%)(66%)20%(124%)
EBIT Margin(229%)(152%)(90%)(38%)(152%)
Net Profit($54M)($46M)($61M)$7M($46M)
Net Margin(199%)(133%)(126%)10%(133%)

Financial data powered by Morningstar, Inc.

Precision BioSciences Stock Performance

Precision BioSciences has current market cap of $197M, and enterprise value of $110M.

Market Cap Evolution


Precision BioSciences' stock price is $7.64.

Precision BioSciences share price increased by 6.9% in the last 30 days, and by 58.3% in the last year.

Precision BioSciences has an EPS (earnings per share) of $-1.77.

See more trading valuation data for Precision BioSciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$110M$197M5.0%6.9%82.0%58.3%$-1.77

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Precision BioSciences Valuation Multiples

Precision BioSciences trades at 4.1x EV/Revenue multiple, and (2.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Precision BioSciences

EV / Revenue (LTM)


Precision BioSciences Financial Valuation Multiples

As of May 5, 2026, Precision BioSciences has market cap of $197M and EV of $110M.

Precision BioSciences has a P/E ratio of (3.7x).

LTMLast FY202320242025202620272028
EV/Revenue4.1x3.2x2.3x1.6x3.2x
EV/EBITDA(2.1x)(2.6x)(3.4x)8.2x(2.6x)
EV/EBIT(1.8x)(2.1x)(2.5x)(4.2x)(2.1x)
EV/Gross Profit4.1x————
P/E(3.7x)(4.3x)(3.2x)27.5x(4.3x)
EV/FCF(2.3x)(1.7x)(1.3x)(1.9x)(1.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Precision BioSciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Precision BioSciences Margins & Growth Rates

In the most recent fiscal year, Precision BioSciences reported EBITDA margin of (124%) and net margin of (133%).

See estimated margins and future growth rates for Precision BioSciences

Precision BioSciences Margins

Last FY20242025202720282029
EBITDA Margin(124%)20%(124%)
EBIT Margin(152%)(38%)(152%)
Net Margin(133%)10%(133%)
FCF Margin(194%)(85%)(194%)

Precision BioSciences Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth41%(50%)
EBITDA Growth(142%)(414%)
EBIT Growth(40%)99%
Net Profit Growth(112%)(738%)
FCF Growth(32%)13%

Data powered by FactSet, Inc. and Morningstar, Inc.

Precision BioSciences Operational KPIs

Precision BioSciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.8M for the same period.

Access forward-looking KPIs for Precision BioSciences
LTMLast FY202320242025202620272028
Rule of 40(251%)————
Bessemer Rule of X(329%)————
Revenue per Employee—$0.3M———
Opex per Employee—$0.8M———
G&A Expenses to Revenue—94%80%51%94%
R&D Expenses to Revenue210%158%110%87%158%
Opex to Revenue—252%190%138%252%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Precision BioSciences Competitors

Precision BioSciences competitors include Pyridam Farma, PhotoCure, Atrium Therapeutics, Camp4 Therapeutics, Medeze Group, Elicio Therapeutics, Macrogenics, Cartesian Therapeutics, OmniAb and Humacyte.

Most Precision BioSciences public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Pyridam Farma2.9x—(69.9x)—
PhotoCure3.0x2.8x42.2x20.6x
Atrium Therapeutics(3.6x)(5.5x)0.9x—
Camp4 Therapeutics26.6x24.8x(1.8x)(1.3x)
Medeze Group6.6x—17.1x—
Elicio Therapeutics——(5.3x)—
Macrogenics0.3x0.4x(0.8x)—
Cartesian Therapeutics34.6x49.2x(1.2x)—

This data is available for Pro users. Sign up to see all Precision BioSciences competitors and their valuation data.

Start Free Trial

Precision BioSciences Funding History

Before going public, Precision BioSciences raised $136M in total equity funding, across 2 rounds.


Precision BioSciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-18Series BArrowMark Partners; venBio Partners$110M—Precision BioSciences, a Durham, North Carolina-based genome editing company, closed an oversubscribed $110 million Series B financing on June 26, 2018, led by ArrowMark Partners with participation from new investors including Franklin Templeton Investments, Cowen Healthcare Investments, Brace Pharma Capital, Pontifax AgTech, OCV Partners, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Alexandria Venture Investments, Ridgeback Capital, Agent Capital, and Leerink Partners affiliates, as well as existing investors venBio, F-Prime, RA Capital Management, Amgen Ventures, Osage University Partners, DUMAC, and the Longevity Fund. The proceeds were intended to advance the company's ARCUS genome editing platform, a proprietary homing endonuclease-derived technology, across immuno-oncology, genetic disease, and food applications. Specific plans included advancing its lead off-the-shelf CAR-T product into clinical trials, progressing its lead in vivo gene therapy program to IND-enabling studies, and initiating field trials for its food program. Tony Yao from ArrowMark Partners joined the Precision BioSciences board alongside existing directors Matt Kane (CEO), Derek Jantz (CSO), and Robert Adelman from venBio. The company aims to build a fully integrated biotechnology firm leveraging ARCUS's small size and high specificity for precise genome editing. ARCUS nuclease is a synthetic enzyme customizable to target specific DNA sequences. By March 2019, ahead of its IPO, Precision had raised approximately $317 million cumulatively from preferred stock, convertible notes, a Servier upfront payment, and other alliances/grants, with investors including those from the Series B. The firm was developing allogeneic CAR-T immunotherapy, in vivo gene correction, and food applications, with FDA acceptance of an IND for its CD19-targeting CAR-T candidate and experience in crop genome editing for partners addressing agriculture challenges.
May-15Series AAmgen Ventures; Baxter Ventures; Eight Roads Ventures; F-Prime; OUP (Osage University Partners); RA Capital Management; The Longevity Fund; venBio Partners; Ziegler Link-Age Funds$26M—Precision BioSciences, a genome editing company based in Research Triangle Park, North Carolina, closed a $25.6 million Series A financing on May 11, 2015, led by venBio Partners. The oversubscribed round included investors such as Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, and the Longevity Fund, matching the specified investors including Eight Roads Ventures (possibly aligned with Fidelity), F-Prime, RA Capital Management, and Ziegler Link-Age Funds in broader participation. Robert Adelman of venBio and Ben Auspitz of Fidelity Biosciences joined the board alongside CEO Matthew Kane and CSO Derek Jantz. venBio, the lead, focuses on clinical-stage life sciences companies and novel technologies. The funding was designated to propel translational development of Precision's ARCUS genome editing platform and accelerate the genome-edited product pipeline addressing needs in human health, agriculture, and beyond. Precision's vision positioned it as a conduit for solving major genome engineering challenges through next-generation editing technologies.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Precision BioSciences

When was Precision BioSciences founded?Precision BioSciences was founded in 2006.
Where is Precision BioSciences headquartered?Precision BioSciences is headquartered in United States.
How many employees does Precision BioSciences have?As of today, Precision BioSciences has over 108 employees.
Who is the CEO of Precision BioSciences?Precision BioSciences' CEO is Michael Amoroso.
Is Precision BioSciences publicly listed?Yes, Precision BioSciences is a public company listed on Nasdaq.
What is the stock symbol of Precision BioSciences?Precision BioSciences trades under DTIL ticker.
When did Precision BioSciences go public?Precision BioSciences went public in 2019.
Who are competitors of Precision BioSciences?Precision BioSciences main competitors include Pyridam Farma, PhotoCure, Atrium Therapeutics, Camp4 Therapeutics, Medeze Group, Elicio Therapeutics, Macrogenics, Cartesian Therapeutics, OmniAb, Humacyte.
What is the current market cap of Precision BioSciences?Precision BioSciences' current market cap is $197M.
What is the current revenue of Precision BioSciences?Precision BioSciences' last 12 months revenue is $27M.
What is the current revenue growth of Precision BioSciences?Precision BioSciences revenue growth (NTM/LTM) is (52%).
What is the current EV/Revenue multiple of Precision BioSciences?Current revenue multiple of Precision BioSciences is 4.1x.
Is Precision BioSciences profitable?No, Precision BioSciences is not profitable.
What is the current EBITDA of Precision BioSciences?Precision BioSciences has negative EBITDA and is not profitable.
What is Precision BioSciences' EBITDA margin?Precision BioSciences' last 12 months EBITDA margin is (199%).
What is the current EV/EBITDA multiple of Precision BioSciences?Current EBITDA multiple of Precision BioSciences is (2.1x).
What is the current FCF of Precision BioSciences?Precision BioSciences' last 12 months FCF is ($49M).
What is Precision BioSciences' FCF margin?Precision BioSciences' last 12 months FCF margin is (180%).
What is the current EV/FCF multiple of Precision BioSciences?Current FCF multiple of Precision BioSciences is (2.3x).
How many companies Precision BioSciences has acquired to date?Precision BioSciences hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Precision BioSciences has invested to date?Precision BioSciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Precision BioSciences

Lists including Precision BioSciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial